Overview

The burgeoning domain of therapeutic oligonucleotides—encompassing antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs)—heralds a transformative epoch in precision medicine, facilitating direct engagement with hitherto intractable genes and their regulatory machinery. These succinct, synthetically engineered DNA or RNA strands exercise precise modulation of genetic expression. The pivotal determinant for realizing their complete therapeutic potential resides in deliberate chemical alteration. Our specialized oligonucleotide modification service at CD BioGlyco is meticulously calibrated to surmount extant pharmacokinetic and pharmacodynamic constraints. Through the strategic incorporation of proprietary and established modifications targeting the nucleobase, sugar moiety, or phosphate backbone, we convert preliminary oligo sequences into potent, durable, and cell-permeant drug candidates. This offering is indispensable for expediting the hit-to-lead progression and lead refinement phases within nucleic acid pharmaceutical development, guaranteeing that candidates exhibit superior stability, enhanced binding affinity, and targeted tissue delivery.

Core Technologies

Our service is built upon a versatile, state-of-the-art platform encompassing the full spectrum of chemical and structural modifications necessary for next-generation oligonucleotide therapeutics.

• Backbone and Sugar Chemistries for Stability and Affinity

The stability and target binding affinity of an oligonucleotide are fundamentally controlled by its backbone and sugar chemistry. We offer all clinically validated modifications:

• Phosphorothioate (PS) Linkages

The most common backbone modification, where a non-bridging oxygen is replaced by sulfur. PS linkages significantly confer nuclease resistance, which is vital for extending the in vivo half-life and promoting cellular uptake.

• 2'-O-Methoxyethyl (2'-MOE) and 2'-Fluoro (2'-F)

These sugar modifications increase nuclease resistance and enhance the binding affinity to the target RNA. 2'-MOE is particularly utilized in the "wings" of ASO gapmers to increase affinity and shield the RNase H-competent region.

• Conformationally Constrained Nucleotides (LNA/BNA)

LNA and other BNA analogs constrain the ribose ring, leading to unprecedented increases in target binding affinity and stability, enabling the design of shorter, more potent oligonucleotides.

A Complete Portfolio of Therapeutic Oligonucleotides

• Our streamlined oligonucleotide development workflow ensures precision and transparency from design to delivery. It begins with a collaborative consultation to review your sequence, target mechanism (ASO, siRNA, SSO), and biological objectives. Our experts partner with you to optimize chemotype selection, modification patterns—such as gapmer design and wing chemistry—and conjugation strategies, including ligand choice and attachment site.
• Synthesis employs solid-support phosphoramidite chemistry using advanced synthesizers and proprietary cycles for high-efficiency incorporation of both standard and modified monomers (e.g., PS, 2'-MOE, LNA). After cleavage and deprotection, site-specific conjugation of ligands like GalNAc, peptides, or fluorophores is performed under optimized solution-phase or solid-phase conditions.
• Purification utilizes high-resolution HPLC (IEX and RP-HPLC) to achieve high purity, including resolution of complex stereoisomer mixtures from PS linkages. Rigorous QC follows, employing MS for identity confirmation, analytical HPLC for purity, and stability assays when required. Each batch is accompanied by a comprehensive certificate of analysis and supporting regulatory documentation.

Workflow

Publication Data

Applications

• Augmentation of Nuclease Resistance and Metabolic Stability

Our service can be used to significantly enhance the stability of oligonucleotides against degradation by nucleases in blood and tissues, thereby prolonging their half-life and therapeutic effect.

• Optimization of Pharmacokinetic Profiles and Biodistribution

Our service can be used to improve the absorption, distribution, and cellular uptake of oligonucleotides, leading to more favorable pharmacokinetic properties and increased bioavailability at the target site.

• Amplification of Target Binding Affinity and Specificity

Our service can be used to strengthen the hydrogen bonding and hydrophobic interactions between the oligonucleotide and its target mRNA, resulting in heightened binding affinity and reduced off-target effects.

• Reduction of Unwanted Immunostimulation

Our service can be used to mitigate unintended activation of the innate immune system by strategically modifying certain sequence motifs recognized by immune receptors.

• Facilitation of Tissue-Specific Delivery and Cellular Internalization

Our service can be used to conjugate ligands or design chemistries that promote receptor-mediated uptake in specific cell types, enabling targeted delivery and improving intracellular trafficking.

• Acceleration of Hit-to-Lead and Lead Optimization Processes

Our service can be used to rapidly generate and screen a diverse library of modified candidates, streamlining the early-stage drug discovery pipeline for nucleic acid therapeutics.

Advantages

• Unparalleled Purity and Quality
  We guarantee industry-leading purity levels, achieved through a combination of ultra-efficient synthesis cycles and rigorous multi-stage HPLC purification.
• Expertise in Complex Modifications
  The efficacy of modern therapeutic oligos is dependent on sophisticated chemical modifications (e.g., novel sugar analogs, complex ligands, unique prodrug assemblies).
• Consultative Partnership
  We operate as an extension of your research team. Our scientific specialists provide pre-synthesis consultation and troubleshooting support throughout your entire development lifecycle.
• Proprietary Modification Platforms and Repertoire
  We have developed a robust portfolio of proprietary phosphoramidites and conjugation reagents, enabling access to novel modifications beyond industry standards. This includes unique backbone chemistries, advanced stereocontrolled linkages, and custom-designed targeting ligands that can provide your candidates with a critical competitive edge.
• Scalability and Reproducible Manufacturing
  We maintain stringent process controls and rigorous quality assurance protocols to ensure impeccable reproducibility and lot-to-lot consistency, providing a reliable path from discovery to clinical trials.

Frequently Asked Questions

Customer Review

• "The CD BioGlyco team successfully synthesized our triplex GalNAc-siRNA conjugate, which was notoriously challenging due to the purity requirements of the final conjugate. Their dedication to QC was outstanding. Highly recommend."

— Dr. Hayes, Senior Investigator, Translational Medicine

• "We needed a large batch of 2'-MOE/PS chimeric ASOs for our tox studies. CD BioGlyco delivered the material ahead of schedule with all required documentation."

— Manager, Drug Manufacturing

• "The novel conjugation chemistry they developed for attaching our proprietary peptide to our ASO drastically improved cellular uptake in our models. It was a true collaboration between our science teams."

— Lead Scientist, In Vivo Pharmacology

Associated Services

While our therapeutic oligonucleotide modification service enables precise functionalization of nucleic acid therapeutics, the foundation of these advanced applications relies on high-quality starting materials. Our Chemical-based Oligonucleotide Synthesis Service provides this essential groundwork through both Solid-phase and Liquid-phase chemical synthesis platforms, offering comprehensive solutions for oligonucleotide production.

CD BioGlyco positions itself as a specialized collaborator for advancing precision medicine, offering a service focused on modifying therapeutic oligonucleotides. By integrating deep scientific experience with ongoing innovation in chemical synthesis, the company facilitates a continuous and efficient operational pathway, guiding each project from initial concept through to the completion of a rigorously refined end product. Contact us to enhance molecular stability, improve targeting accuracy, and increase pharmacological potency—attributes essential for transforming genetic discoveries into promising drug candidates.